重组人白细胞介素Ⅱ治疗初发急性白血病化疗后血小板减少的疗效观察  

The Efficacy of Recombinant Human Interleukin-Ⅱ in Chemotherapy-Induced Thrombocytopenia of Initial Acute Leukemia

作　　者：章志学[1] 肖牛明[1] 罗立新[1] 

机构地区：[1]吉安市中心人民医院血液内科,江西吉安343100

出　　处：《中国中医药咨讯》2011年第12期114-115,共2页

摘　　要：目的：观察重组人白细胞介素Ⅱ（rhIL-Ⅱ）治疗初发急性白血病化疗后血小板减少的临床疗效及不良反应方法：20例初发急性白血病患者，诱导化疗结束后rhIL-Ⅱ 1．5mg／d皮下注射，连用7-14天，对照组23例同期住院的初发急性自血病患者，诱导化疗后不用rhIL-Ⅱ，对比观察组疗效。结果：治疗组注射rhIL-Ⅱ后血小板恢复至≥30×109／L、≥50×109／L、≥100×109／L的平均时间均早于对照组（P〈O．05），输注机采血小板数量少，两组比较差异有统计学意义（P〈O．05），患者常见的不良反应有肌肉关节酸痛，水肿、发热，乏力、恶心，程度较轻，停药后消失。结论：rhIL-Ⅱ治疗初发急性自血病诱导化疗后血小板疗效好，安全，可缩短血小板恢复的时间，减少血小板量的输注。Objective ：To observe the efficacy, safety and possible mechanism of recombinant human interleukin-Ⅱ （ rhIL-Ⅱ ）in chemotherapy induced thrombocytopenia of initial acute leukemia. Methods 20 initial acute leukemia patients were treated with rhIL-Ⅱ after the completion of chemotherapy at 1.5mg/d, injection for 7 - 14 days. 25 acute leukemia patients during the same time entered into the control group. Results The meantime of platelet count≥ 30 ×109/L, 50 × 109/L, 100 × 109/L in the patients who received rhIL-Ⅱ was less than that of control group （P〈0.05）. And this treatment policy can significantly reduce the platelet transfusions.（P〈0.05） Major adverse events associated with rhIL- Ⅱ were fatigue, edema, nausea, callosity and so on. They were mild, reversible with drug discon- tinuation and easily managed Conclusion RhIL- Ⅱ can safely accelerate the recovery of chemotherapy induced thrombocytopenia in initial acute leukemia,Shorten the recovery time of platelet, reduce the amount of platelet transfusion.

关 键 词：初发急性白血病 白细胞介素Ⅱ 血小板减少 疗效观察 化疗后 治疗组 重组 急性白血病患者 

分 类 号：R733.71[医药卫生—肿瘤]